Finch Therapeutics Group, Inc.

For patients in the US with recurrent Clostridioides difficile infection (rCDI), the recent approval of two safe and effective treatments is a win. Now the question for Seres Therapeutics, Inc. an

Ferring Pharmaceuticals has been looking back at an eventful 2022 which saw potentially game-changing approvals in the US for its microbiome and gene therapies and record revenues for the Swiss group

The market for initial public offerings by biopharmaceutical companies declined to just 22 IPOs in the US in 2022 and it has gotten off to a slow start in 2023 with just three small offerings to date,

Finch Therapeutics Group, Inc. battled to keep its microbiome-focused programs going through two workforce reductions in 2022, but now it appears to be ceding the fight. On 24 January, the Somerville